BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 21860026)

  • 21. Multiple myeloma cells' capacity to decompose H
    Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
    Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ARID2 is a pomalidomide-dependent CRL4
    Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
    Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
    Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
    Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs.
    Gemechu Y; Millrine D; Hashimoto S; Prakash J; Sanchenkova K; Metwally H; Gyanu P; Kang S; Kishimoto T
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):11802-11807. PubMed ID: 30373817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunomodulatory drugs (IMiDs)].
    Oshima K; Ichinohe T
    Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
    Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
    Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
    ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
    Yang DY; Ren JH; Guo XN; Guo XL; Cai XY; Guo XF; Zhang JN
    Genet Mol Res; 2015 Oct; 14(4):13588-94. PubMed ID: 26535672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
    Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
    Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
    Das DS; Ray A; Song Y; Richardson P; Trikha M; Chauhan D; Anderson KC
    Br J Haematol; 2015 Dec; 171(5):798-812. PubMed ID: 26456076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
    Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
    Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
    [No Abstract]   [Full Text] [Related]  

  • 36. The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
    Zou J; Jones RJ; Wang H; Kuiatse I; Shirazi F; Manasanch EE; Lee HC; Sullivan R; Fung L; Richard N; Erdman P; Torres E; Hecht D; Lam I; McElwee B; Chourasia AH; Chan KWH; Mercurio F; Stirling DI; Orlowski RZ
    J Mol Med (Berl); 2020 Aug; 98(8):1161-1173. PubMed ID: 32632752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of cereblon levels by anti-myeloma agents.
    Díaz-Rodríguez E; Pandiella A
    Leuk Lymphoma; 2016; 57(1):167-76. PubMed ID: 25860244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
    Bedewy AM; El-Maghraby SM
    Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.